Independent Research Reiterates “€97.00” Price Target for MorphoSys (MOR)

Independent Research set a €97.00 ($119.75) price target on MorphoSys (ETR:MOR) in a research report released on Tuesday morning. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on MOR. Berenberg Bank set a €85.00 ($104.94) price target on MorphoSys and gave the company a buy rating in a research note on Tuesday. Royal Bank of Canada set a €57.00 ($70.37) price target on MorphoSys and gave the company a sell rating in a research note on Tuesday. JPMorgan Chase & Co. restated a buy rating and issued a price target on shares of MorphoSys in a research note on Tuesday. Commerzbank set a €98.00 ($120.99) price target on MorphoSys and gave the company a buy rating in a research note on Monday, March 12th. Finally, Deutsche Bank set a €94.00 ($116.05) price target on MorphoSys and gave the company a buy rating in a research note on Monday, March 12th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company currently has an average rating of Hold and a consensus target price of €84.02 ($103.73).

How to Become a New Pot Stock Millionaire

Shares of MorphoSys (ETR MOR) opened at €83.90 ($103.58) on Tuesday. MorphoSys has a 12 month low of €49.63 ($61.27) and a 12 month high of €88.10 ($108.77). The stock has a market capitalization of $2,490.00 and a P/E ratio of -34.81.

COPYRIGHT VIOLATION WARNING: “Independent Research Reiterates “€97.00” Price Target for MorphoSys (MOR)” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3269752/independent-research-reiterates-97-00-price-target-for-morphosys-mor.html.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Schneider Electric  Given a €88.00 Price Target by Societe Generale Analysts
Schneider Electric Given a €88.00 Price Target by Societe Generale Analysts
Essilor International  Given a €104.40 Price Target at JPMorgan Chase
Essilor International Given a €104.40 Price Target at JPMorgan Chase
Berenberg Bank Analysts Give Danone  a €72.50 Price Target
Berenberg Bank Analysts Give Danone a €72.50 Price Target
Zooplus  Given a €140.00 Price Target by Kepler Capital Markets Analysts
Zooplus Given a €140.00 Price Target by Kepler Capital Markets Analysts
Reviewing Government Properties Income Trust  and Innovative Industrial
Reviewing Government Properties Income Trust and Innovative Industrial
Sky Solar  & Its Rivals Head-To-Head Comparison
Sky Solar & Its Rivals Head-To-Head Comparison


© 2006-2018 Ticker Report. Google+.